首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 以基因為基之藥物開發

市場調查報告書

商品編碼

1677775

表觀遺傳學：技術與全球市場

Epigenetics: Technologies and Global Markets

出版日期: 2025年03月04日 | 出版商:

BCC Research | 英文 115 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球表觀遺傳學研究工具和試劑、IVD 和治療市場規模預計將從 2024 年的 48 億美元成長到 2029年終的 85 億美元，預測期內的複合年成長率為 11.8%。

基於表觀遺傳生物標記的 IVD 領域預計將從 2024 年的 19 億美元成長到 2029年終的44 億美元，複合年成長率為 18.0%。表觀遺傳學研究工具和試劑部分預計將從 2024 年的 18 億美元成長到 2029年終的22 億美元，複合年成長率為 4.1%。

本報告調查了全球表觀遺傳學市場，並提供了市場概況的摘要、市場影響因素和市場機會的分析、法律制度、新興技術和技術發展的趨勢、市場規模的趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業的概況。

市場動態：概覽
市場促進因素
癌症發生率上升和腫瘤學領域未滿足的需求
分析技術和工具的進步
增加對生物醫學研究的投資
精準醫療的趨勢
人們對液態生物檢體的興趣日益濃厚
市場限制
從實驗室到臨床：表觀遺傳學中的轉化差距
表觀遺傳治療：固態腫瘤臨床成功率有限
監理環境嚴峻
市場趨勢
將表觀遺傳修飾劑與其他治療層級結合
多組體學整合
用於表觀遺傳學研究的長讀測序
基於表觀遺傳生物標記的癌症篩檢血液檢測

第4章新興科技與發展

新興技術
表觀基因編輯
表觀轉錄組學
BET 抑制劑
腦膜炎球菌抑制劑
腫瘤學以外的應用
管道分析
概述
處於第 2 期或更高階段開發的新型表觀遺傳藥物

第5章市場區隔分析

細分市場
表觀遺傳學研究工具和試劑市場（按研究方法）
市場概況
市場規模及預測
DNA甲基化
組蛋白修飾
RNA修飾
體外診斷 (IVD) 市場（依臨床適應症）
市場概況
市場規模及預測
表觀遺傳治療市場（依藥物類別）
市場概況
市場規模及預測
地理分佈
表觀遺傳學研究工具和試劑市場（按地區）
市場規模及預測
北美洲
歐洲
亞太地區
其他地區

第6章競爭訊息

研究工具和試劑
體外診斷
治療

第 7 章表觀遺傳學市場的永續性：ESG 視角

ESG：簡介
表觀遺傳藥物和診斷市場的關鍵 ESG 問題
製藥製造業的永續性實踐
永續包裝
表觀遺傳學研究工具市場中的關鍵 ESG 議題
ESG 風險評估評分 – 理解資料
結論

第 8 章附錄

調查方法
來源
簡稱
公司簡介
ACTIVE MOTIF INC.
BIO-RAD LABORATORIES INC.
BIO-TECHNE
BRISTOL-MYERS SQUIBB CO.
DAIICHI SANKYO CO. LTD.
EXACT SCIENCES CORP.
GUARDANT HEALTH
HOLOGIC INC.
LES LABORATOIRES SERVIER
MERCK KGAA
NUCLEIX
PROMEGA CORP.
QIAGEN
REVVITY INC. (PERKINELMER)
THERMO FISHER SCIENTIFIC INC.

簡介目錄圖表

Product Code: PHM044D

The global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029.

The global market for epigenetic biomarker-based IVDs is expected to grow from $1.9 billion in 2024 to $4.4 billion by the end of 2029, at a CAGR of 18.0% from 2024 through 2029.

The global market for epigenetics research tools and reagents is expected to grow from $1.8 billion in 2024 to $2.2 billion by the end of 2029, at a CAGR of 4.1% from 2024 through 2029.

Report Scope

This report comprehensively analyzes the global market for epigenetics products, research tools and reagents, epigenetic biomarker-based in vitro diagnostics (IVDs) and epigenetics-targeted therapeutics. It offers both quantitative and qualitative insights to help readers formulate growth strategies, evaluate the market landscape, assess their competitive positions and make informed business decisions regarding epigenetics products and services. The scope of epigenetics-targeted therapeutics includes DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, isocitrate dehydrogenase (IDH) inhibitors and zeste homolog 2 (EZH2) inhibitors.

In this report, BCC Research estimated market data for 2023 (base year) and forecasts values for 2024 through 2029. The research tools and reagents market segmentation is based on the study methods. Epigenetic biomarker-based IVDs market segmentation is based on clinical indications. Epigenetics targeted therapeutics market segmentation is based on drug class. This report also provides regional analyses for epigenetics products.

This report analyzes industry growth drivers, restraints, trends and opportunities in the epigenetics market. The report also covers the competitive landscape and latest trends in epigenetics products. Emerging technologies that impact the epigenetics market are also discussed, along with current information about new products, acquisitions and collaborations related to the epigenetics market.

Report Includes

25 data tables and 66 additional tables
Analyses of the trends in global markets for epigenetics technologies, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
Estimates of the size and growth forecasts of the global epigenomics market, and a corresponding market share analysis by product type, study method, clinical indication, drug class and region
Facts and figures pertaining to the market dynamics, technological advancements, regulatory landscape, and the impact of macroeconomic factors
Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
Evaluation of recent patent activity and key granted and published patents in the industry
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Profiles of leading companies, including Bristol-Myers Squibb Co., Les Laboratoires Servier, Exact Sciences Corp., Thermo Fisher Scientific Inc., and Qiagen

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Epigenetics Overview
DNA Methylation
Histone Modification
RNA Modifications
Epigenetic Modulators

Chapter 3 Market Dynamics

Market Dynamics Snapshot
Market Drivers
Rising Prevalence of Cancer and Unmet Need in Oncology
Advances in Analytical Technologies and Tools
Increasing Investment in Biomedical Research
Trend Towards Precision Medicine
Growing Interest in Liquid Biopsy
Market Restraints
From Bench to Bedside: The Translation Gap in Epigenetics
Epigenetic Therapeutics: Limited Clinical Success Against Solid Tumors
Stringent Regulatory Landscape
Market Trends
Combining Epigenetic Modifiers with Other Therapeutic Class
Multi-omics Integration
Long-Read Sequencing in Epigenetic Research
Epigenetic Biomarkers-based Blood Test for Cancer Screening

Chapter 4 Emerging Technologies and Developments

Emerging Technologies
Epigenome Editing
Epitranscriptomics
Bromodomain and Extra-Terminal Domain Inhibitors
Menin Inhibitors
Application Beyond Oncology
Pipeline Analysis
Overview
Novel Epigenetic Therapeutics in Development in Phase 2 and Above

Chapter 5 Market Segmentation Analysis

Segmentation Breakdown
Epigenetics Research Tools and Reagents Market, by Study Method
Market Overview
Market Size and Forecast
DNA Methylation
Histone Modification
RNA Modification
In Vitro Diagnostics (IVDs) Market, by Clinical Indication
Market Overview
Market Size and Forecast
Epigenetic Therapeutics Market, by Drug Class
Market Overview
Market Size and Forecast
Geographic Breakdown
Epigenetics Research Tools and Reagents Market, by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World

Chapter 6 Competitive Intelligence

Research Tools and Reagents
In Vitro Diagnostics
Therapeutics

Chapter 7 Sustainability in the Epigenetics Market: An ESG Perspective

Introduction to ESG
Key ESG Issues in Epigenetics Pharmaceuticals and Diagnostics Market
Sustainability Practices in Pharmaceuticals Manufacturing
Sustainable Packaging
Key ESG Issues in Epigenetics Research Tools Market
ESG Risk Ratings Score -- Understanding the Data
Concluding Remarks

Chapter 8 Appendix

Methodology
Sources
Abbreviations
Company Profiles
ACTIVE MOTIF INC.
BIO-RAD LABORATORIES INC.
BIO-TECHNE
BRISTOL-MYERS SQUIBB CO.
DAIICHI SANKYO CO. LTD.
EXACT SCIENCES CORP.
GUARDANT HEALTH
HOLOGIC INC.
LES LABORATOIRES SERVIER
MERCK KGAA
NUCLEIX
PROMEGA CORP.
QIAGEN
REVVITY INC. (PERKINELMER)
THERMO FISHER SCIENTIFIC INC.

簡介目錄圖表

List of Tables

Summary Table : Global Market for Epigenetics Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
Table 1 : Techniques, Advantages and Disadvantages of Common DNA Methylation Analysis Methods
Table 2 : Types of Noncoding (ncRNAs)
Table 3 : Key Programs/Consortiums to Support Epigenetic Research
Table 4 : Epigenetic Biomarker-based Blood Tests Currently Under Clinical Development
Table 5 : Companies Developing Products Based on Epigenome Editing Platforms
Table 6 : BET Inhibitors in Late-Stage Clinical Trials
Table 7 : Menin Inhibitors in Clinical Trials
Table 8 : Novel Epigenetic Therapeutic Candidates in Clinical Trials Phase 2 and Above
Table 9 : Global Market for Epigenetics Research Tools and Reagents, by Study Method, Through 2029
Table 10 : Commercially Available Epigenetic Biomarker-based IVDs for Colorectal Cancer
Table 11 : Commercially Available Epigenetic Biomarker-based IVDs for Bladder Cancer
Table 12 : Commercially Available Epigenetic Biomarker-based IVDs for Cervical Cancer
Table 13 : Commercially Available Epigenetic Biomarker-based IVDs for Other Indications
Table 14 : FDA Breakthrough Device Designated Epigenetic Biomarker-based Clinical Assays Currently Undergoing Clinical Validation
Table 15 : Global Market for Epigenetic Biomarker-based IVDs, by Clinical Indication, Through 2029
Table 16 : Commercially Available DNMT Inhibitors
Table 17 : Commercially Available HDAC Inhibitors
Table 18 : Commercially Available IDH Inhibitors
Table 19 : Commercially Available EZH2 Inhibitors
Table 20 : Global Market for Epigenetic Therapeutics, by Drug Class, Through 2029
Table 21 : Global Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Region, Through 2029
Table 22 : North American Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
Table 23 : North American Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, Through 2029
Table 24 : European Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
Table 25 : European Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, Through 2029
Table 26 : Asia-Pacific Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
Table 27 : Asia-Pacific Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, Through 2029
Table 28 : RoW Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
Table 29 : Global Market Shares of Epigenetic Biomarkers-based IVDs, by Company, 2023
Table 30 : Commercially Available Epigenetics-Targeted Drugs
Table 31 : Key Sustainability Practices in the Pharmaceuticals Industry
Table 32 : ESG Risk Ratings of Key Companies in the Epigenetics Market, 2024
Table 33 : Ethos Impact Inc. Score Card for Key Companies in the Epigenetics Market, 2024
Table 34 : Information Sources for this Report
Table 35 : Abbreviations Used in the Report
Table 36 : Active Motif Inc.: Company Snapshot
Table 37 : Active Motif Inc.: Product Portfolio
Table 38 : Active Motif Inc.: News/Key Developments, 2022
Table 39 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 40 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
Table 41 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 42 : Bio-Rad Laboratories Inc.: News/Key Developments, 2023 and 2024
Table 43 : Bio-Techne: Company Snapshot
Table 44 : Bio-Techne: Financial Performance, FY 2022 and 2023
Table 45 : Bio-Techne: Product Portfolio
Table 46 : Bio-Techne: News/Key Developments, 2023
Table 47 : Bristol-Myers Squibb Co.: Company Snapshot
Table 48 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 49 : Bristol-Myers Squibb Co: Product Portfolio
Table 50 : Daiichi Sankyo Co. Ltd.: Company Snapshot
Table 51 : Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 52 : Daiichi Sankyo Co. Ltd.: Product Portfolio
Table 53 : Daiichi Sankyo Co. Ltd.: News/Key Developments, 2022-2024
Table 54 : Exact Sciences Corp.: Company Snapshot
Table 55 : Exact Sciences Corp.: Financial Performance, FY 2022 and 2023
Table 56 : Exact Sciences Corp.: Product Portfolio
Table 57 : Exact Sciences Corp.: News/Key Developments, 2023 and 2024
Table 58 : Guardant Health: Company Snapshot
Table 59 : Guardant Health: Financial Performance, FY 2022 and 2023
Table 60 : Guardant Health: Product Portfolio
Table 61 : Guardant Health: News/Key Developments, 2023 and 2024
Table 62 : Hologic Inc.: Company Snapshot
Table 63 : Hologic Inc.: Financial Performance, FY 2023 and 2024
Table 64 : Hologic Inc.: Product Portfolio
Table 65 : Les Laboratoires Servier: Company Snapshot
Table 66 : Les Laboratoires Servier: Financial Performance, FY 2022 and 2023
Table 67 : Les Laboratoires Servier: Product Portfolio
Table 68 : Les Laboratoires Servier: News/Key Developments, 2023 and 2024
Table 69 : Merck KGaA: Company Snapshot
Table 70 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 71 : Merck KGaA: Product Portfolio
Table 72 : Merck KGaA: News/Key Developments, 2023 and 2024
Table 73 : Nucleix: Company Snapshot
Table 74 : Nucleix: Product Portfolio
Table 75 : Nucleix: News/Key Developments, 2023 and 2024
Table 76 : Promega Corp.: Company Snapshot
Table 77 : Promega Corp.: Product Portfolio
Table 78 : Promega Corp.: News/Key Developments, 2023
Table 79 : Qiagen: Company Snapshot
Table 80 : Qiagen: Financial Performance, FY 2022 and 2023
Table 81 : Qiagen: Product Portfolio
Table 82 : Qiagen: News/Key Developments, 2023 and 2024
Table 83 : Revvity Inc. (PerkinElmer): Company Snapshot
Table 84 : Revvity Inc. (PerkinElmer): Financial Performance, FY 2022 and 2023
Table 85 : Revvity Inc. (PerkinElmer): Product Portfolio
Table 86 : Revvity Inc. (PerkinElmer): News/Key Developments, 2023
Table 87 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 88 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 89 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 90 : Thermo Fisher Scientific Inc.: News/Key Developments, 2024

List of Figures

Summary Figure : Global Market Shares of Epigenetics Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
Figure 1 : Market Dynamics of Epigenetics
Figure 2 : Estimated New Cancer Cases Globally, 2022, 2045 and 2050
Figure 3 : Global Blood Cancer Incidence, by Cancer Type, 2022 vs. 2045
Figure 4 : PubMed Article Count: "Epigenetic," 2018-2024
Figure 5 : Overcoming Barriers in the Clinical Application of Epigenetics
Figure 6 : PubMed Article Count: "Epitranscriptomic" and "RNA Modification," 2021-2024
Figure 7 : Trends in Clinical Trials for Epigenetic Therapeutic Agents, by Drug Class, as of December 2024
Figure 8 : Global Market Shares of Epigenetics Research Tools and Reagents, by Study Method, 2023
Figure 9 : Global Market Shares of Epigenetic Biomarker-based IVDs, by Clinical Indication, 2023
Figure 10 : Global Market Shares of Epigenetic Therapeutics, by Drug Class, 2023
Figure 11 : Global Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Region, 2023
Figure 12 : North American Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
Figure 13 : North American Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, 2023
Figure 14 : European Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
Figure 15 : European Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, 2023
Figure 16 : Worldwide Incidence of Blood Cancer Cases, by Region, 2022
Figure 17 : Asia-Pacific Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
Figure 18 : Asia-Pacific Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, 2023
Figure 19 : RoW Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
Figure 20 : Principle Competitive Factors in Epigenetics Research Tools Market
Figure 21 : Global Market Shares of Leading Manufacturers of Epigenetics-Targeted Therapeutics, 2023
Figure 22 : Selected Factors Driving ESG
Figure 23 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2023
Figure 24 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2023
Figure 25 : Bio-Techne: Revenue Share, by Business Unit, FY 2023
Figure 26 : Bio-Techne: Revenue Share, by Country/Region, FY 2023
Figure 27 : Bristol-Myers Squibb Co: Revenue Share, by Business Unit, FY 2023
Figure 28 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 29 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 30 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 31 : Exact Sciences Corp.: Revenue Share, by Business Unit, FY 2023
Figure 32 : Exact Sciences Corp.: Revenue Share, by Country/Region, FY 2023
Figure 33 : Guardant Health: Revenue Share, by Business Unit, FY 2023
Figure 34 : Guardant Health: Revenue Share, by Country/Region, FY 2023
Figure 35 : Hologic Inc.: Revenue Share, by Business Unit, FY 2024
Figure 36 : Hologic Inc.: Revenue Share, by Country/Region, FY 2024
Figure 37 : Les Laboratoires Servier: Revenue Share, by Business Unit, FY 2023
Figure 38 : Les Laboratoires Servier: Revenue Share, by Region, FY 2023
Figure 39 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 40 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 41 : Qiagen: Revenue Share, by Business Unit, FY 2023
Figure 42 : Qiagen: Revenue Share, by Country/Region, FY 2023
Figure 43 : Revvity Inc. (PerkinElmer): Revenue Share, by Business Unit, FY 2023
Figure 44 : Revvity Inc. (PerkinElmer): Revenue Share, by Country/Region, FY 2023
Figure 45 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023
Figure 46 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023